Skip to main content

Table 3 Univariate analysis for overall survival

From: Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity

Variable RR (95% CI) pvalue
Age ≥ 50 years 0.96 (0.68, 1.35) 0.802
ECOG performance status    
   2 – 3 versus 0 – 1 1.49 (1.06, 2.12) 0.024
Hydroxyproline/creatinine ratio (centered) 1.04 (1.02, 1.07) 0.001
Bone-specific alkaline phosphatase (U/L) 1.00 (1.00, 1.01) 0.415
Estrogen-receptor status versus negative    
   Positive 0.67 (0.42, 1.06) 0.085
   Unknown 0.96 (0.64, 1.44) 0.857
Progesterone-receptor status versus negative    
   Positive 0.61 (0.40, 0.93) 0.022
   Unknown 0.70 (0.49, 0.99) 0.047
Sites of metastasis (yes versus no)    
   Bone as only metastatic site 0.90 (0.65, 1.26) 0.553
   Lung 1.43 (0.89, 2.30) 0.139
   Liver 1.12 (0.69, 1.79) 0.653
Time from diagnosis of bone metastases to study entry, years 1.10 (1.00, 1.21) 0.059
Time from cancer diagnosis to study entry, years
Lesion characteristics and numbers
1.00 (0.95, 1.03) 0.630
   ≥ 3 osteolytic versus < 3 osteolytic 1.29 (0.93, 1.80) 0.128
   1 – 2 osteoblastic versus no osteoblastic 0.98 (0.65, 1.48) 0.935
   ≥ 3 osteoblastic versus no osteoblastic 0.75 (0.62, 0.91) 0.003
   1 – 2 mixed versus no mixed 0.81 (0.48, 1.36) 0.423
   ≥ 3 mixed versus no mixed 1.03 (0.67, 1.58) 0.896
Prior fracture (yes versus no) 1.18 (0.78, 1.77) 0.440
Pain scores (centered) 1.07 (1.01, 1.13) 0.034
Prior chemotherapy (yes versus no) 1.85 (0.59, 5.87) 0.294
≥ 2 prior hormonal therapies (yes versus no) 1.31 (0.94, 1.82) 0.110
Prior radiotherapy (yes versus no) 1.15 (0.80, 1.64) 0.464
  1. Values in bold represent statistically significant correlations.
  2. RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.